aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.8363
+0.0117 (1.42%)
At close: Oct 7, 2025, 4:00 PM EDT
0.8304
-0.0059 (-0.71%)
After-hours: Oct 7, 2025, 7:59 PM EDT
aTyr Pharma Revenue
In the year 2024, aTyr Pharma had annual revenue of $235.00K, down -33.43%.
Revenue (ttm)
$235.00K
Revenue Growth
-33.43%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
81.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
| Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
| Dec 31, 2022 | 10.39M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ATYR News
- 4 days ago - aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower – Hagens Berman - GlobeNewsWire
- 7 days ago - Ethos Technologies Targets IPO Amid Positive Insurance Offerings - Seeking Alpha
- 7 days ago - aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman - GlobeNewsWire
- 7 days ago - aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025 - GlobeNewsWire
- 11 days ago - Ethos Files Registration Statement for Proposed Initial Public Offering - GlobeNewsWire
- 14 days ago - aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman - PRNewsWire
- 15 days ago - aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman - GlobeNewsWire
- 18 days ago - Top 3 Health Care Stocks That May Explode In September - Benzinga